PIK3CA Mutation Is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Mutations in the PIK3CA gene occur frequently in breast cancer patients. Activating PIK3CA mutations confer resistance to human epidermal growth factor receptor 2 (HER2)–targeted treatments. In this study, we investigated whether PIK3CA mutations were correlated with treatment response or duration in patients with HER2-positive (HER2+) breast cancer. Materials and Methods We retrospectively reviewed the clinical information of patients with HER2+ breast cancer who received HER2-targeted therapy for early-stage or metastatic cancers. The pathologic complete response (pCR), progression-free survival (PFS), and overall survival were compared between patients with wild-type PIK3CA (PIK3CAw) and those with mutated PIK3CA (PIK3CAm). Next-generation sequencing was combined with examination of PFS associated with anti-HER2 monoclonal antibody (mAb) treatment. Results Data from 90 patients with HER2+ breast cancer were analyzed. Overall, 34 patients (37.8%) had pathogenic PIK3CA mutations. The pCR rate of the PIK3CAm group was lower than that of the PIK3CAw group among patients who received neoadjuvant chemotherapy for early-stage cancer. In the metastatic setting, the PIK3CAm group showed a significantly shorter mean PFS (mPFS) with first-line anti-HER2 mAb. The mPFS of second-line T-DM1 was lower in the PIK3CAm group than that in the PIK3CAw group. Sequencing revealed differences in the mutational landscape between PIK3CAm and PIK3CAw tumors. Conclusion Patients with HER2+ breast cancer with activating PIK3CA mutations had lower pCR rates and shorter PFS with palliative HER2-targeted therapy than those with wild-type PIK3CA. Precise targeted therapy is needed to improve survival of patients with HER2+/PIK3CAm breast cancer.
Abstract
Purpose Mutations in the PIK3CA gene occur frequently in breast cancer patients. Activating PIK3CA mutations confer resistance to human epidermal growth factor receptor 2 (HER2)–targeted treatments. In this study, we investigated whether PIK3CA mutations were correlated with treatment response or duration in patients with HER2-positive (HER2+) breast cancer. Materials and Methods We retrospectively reviewed the clinical information of patients with HER2+ breast cancer who received HER2-targeted therapy for early-stage or metastatic cancers. The pathologic complete response (pCR), progression-free survival (PFS), and overall survival were compared between patients with wild-type PIK3CA (PIK3CAw) and those with mutated PIK3CA (PIK3CAm). Next-generation sequencing was combined with examination of PFS associated with anti-HER2 monoclonal antibody (mAb) treatment. Results Data from 90 patients with HER2+ breast cancer were analyzed. Overall, 34 patients (37.8%) had pathogenic PIK3CA mutations. The pCR rate of the PIK3CAm group was lower than that of the PIK3CAw group among patients who received neoadjuvant chemotherapy for early-stage cancer. In the metastatic setting, the PIK3CAm group showed a significantly shorter mean PFS (mPFS) with first-line anti-HER2 mAb. The mPFS of second-line T-DM1 was lower in the PIK3CAm group than that in the PIK3CAw group. Sequencing revealed differences in the mutational landscape between PIK3CAm and PIK3CAw tumors. Conclusion Patients with HER2+ breast cancer with activating PIK3CA mutations had lower pCR rates and shorter PFS with palliative HER2-targeted therapy than those with wild-type PIK3CA. Precise targeted therapy is needed to improve survival of patients with HER2+/PIK3CAm breast cancer.
참고문헌 (33)
- Gusterson BA, "Prognostic importance of c-erbB-2 expression in breast cancer. International(Ludwig)Breast Cancer Study Group", J Clin Oncol, 10, pp.1049~1056 (1992)
- Tsongalis GJ, "HER2 : the neu prognostic marker for breast cancer", Crit Rev Clin Lab Sci, 38, pp.167~182 (2001)
- Pohlmann PR, "Resistance to trastuzumab in breast cancer", Clin Cancer Res, 15, pp.7479~7491 (2009)
- Harbeck N, "Randomized phase III trial of afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one prior trastuzumab treatment : LUX-Breast 1", Cancer Res, 75(9 Suppl), pp.P5-19-01~ (2015)
- Wong HH, "Trastuzumab beyond progression in advanced breast cancer : national guidance versus oncologist’s decision", Oncology, 86, pp.22~23 (2014)
- "Breast cancer 2021" (2021)[URL]
- Cardoso F, "5th ESO-ESMO international consensus guidelines for advanced breast cancer(ABC 5)", Ann Oncol, 31, pp.1623~1649 (2020)
- Kataoka Y, "Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines", Ann Oncol, 21, pp.255~262 (2010)
- Cizkova M, "Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab", Br J Cancer, 108, pp.1807~1809 (2013)
- Esteva FJ, "PTEN, PIK3CA, p-AKT, and p-p70S6K status : association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer", Am J Pathol, 177, pp.1647~1656 (2010)
- Liu P, "Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms", Nat Med, 17, pp.1116~1120 (2011)
- Vivanco I, "The phosphatidylinositol 3-Kinase AKT pathway in human cancer", Nat Rev Cancer, 2, pp.489~501 (2002)
- Loibl S, "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer : pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab", Ann Oncol, 27, pp.1519~1525 (2016)
- 이영우, "Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER project", Cancer Research and Treatment, 53(1), pp.123~130 (2021), 대한암학회[DOI]
- Schwartz LH, "RECIST 1. 1-update and clarification : from the RECIST committee", Eur J Cancer, 62, pp.132~137 (2016)
- Clynes RA, "Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets", Nat Med, 6, pp.443~446 (2000)
- Molina MA, "Trastuzumab(herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells", Cancer Res, 61, pp.4744~4749 (2001)
- Yakes FM, "Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action", Cancer Res, 62, pp.4132~4141 (2002)
- Berns K, "A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer", Cancer Cell, 12, pp.395~402 (2007)
- Majewski IJ, "PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer", J Clin Oncol, 33, pp.1334~1339 (2015)
- Rimawi MF, "Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer", Breast Cancer Res Treat, 167, pp.731~740 (2018)
- Bianchini G, "Biomarker analysis of the NeoSphere study : pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer", Breast Cancer Res, 19, pp.16~ (2017)
- Guarneri V, "PIK3CA mutation in the ShortHER Randomized Adjuvant Trial for patients with early HER2(+)breast cancer : association with prognosis and integration with PAM50 subtype", Clin Cancer Res, 26, pp.5843~5851 (2020)
- Loi S, "Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer", J Natl Cancer Inst, 105, pp.960~967 (2013)
- Yuan H, "Association of PIK3CA mutation status before and after neoadjuvant chemotherapy with response to chemotherapy in women with breast cancer", Clin Cancer Res, 21, pp.4365~4372 (2015)
- 김성배, "BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy", Cancer Research and Treatment, 51(4), pp.1527~1539 (2019), 대한암학회
- Scaltriti M, "Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor", Clin Cancer Res, 16, pp.2688~2695 (2010)
- Patra S, "BRAF, KRAS and PIK3CA mutation and sensitivity to trastuzumab in breast cancer cell line model", Asian Pac J Cancer Prev, 18, pp.2209~2213 (2017)
- Garay JP, "Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA", Breast Cancer Res, 23, pp.81~ (2021)
- Baselga J, "Biomarker analyses in CLEOPATRA : a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer", J Clin Oncol, 32, pp.3753~3761 (2014)
- Kim SB, "Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine(T-DM1)vs. treatment of physician’s choice in previously treated HER2-positive advanced breast cancer", Int J Cancer, 139, pp.2336~2342 (2016)
- Cameron D, "A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab : updated efficacy and biomarker analyses", Breast Cancer Res Treat, 112, pp.533~543 (2008)
- Martinez-Saez O, "Frequency and spectrum of PIK3CA somatic mutations in breast cancer", Breast Cancer Res, 22, pp.45~ (2020)